Abstract

Recent years, it is a highly debated topic that whether methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and A1298C polymorphism could increase susceptibility to venous thromboembolism (VTE) in the Asian and Caucasian. Therefore, we expect to settle that controversy evidentially. Basic methods: Electronic databases (Pubmed, embase, Cochrane library, scopus, OvidSP, Wiley Online library, Springer link, EBSCO, Elsevier Science Direct, Google scholar) without date limitation were searched. Crude odds ratio (OR) along with 95% confidence interval (95% CI) was calculated to assess the association quantitatively. Finally, a total of 37 eligible studies were included, containing 31 for MTHFR C677T polymorphism and 6 for MTHFR A1298C polymorphism. The pooled results suggested that MTHFR C677T mutation may increase susceptibility to VTE in reverse recessive model (CC+CT vs TT): OR = 0.68 (0.56, 0.83), reverse dominant model (CC vs CT +TT): OR = 0.82 (0.72, 0.94), heterozygote model (CT vs TT): OR = 0.65 (0.52, 0.81), homozygote model (CC vs TT): OR = 0.73 (0.60, 0.89) and allele model (C vs T): OR = 0.80 (0.71, 0.90). Subgroup analysis about Asian also support that results, but Caucasian group not. In addition, MTHFR A1298C polymorphism may be not related to VTE in all genetic model. The results of meta-analysis indicated that MTHFR C677T polymorphism might increase the risk of VTE, especially in Asian population.

Introduction

Venous thromboembolism (VTE) is a common clinical vascular syndrome, consisting of deep vein thrombosis (DVT) and pulmonary embolism (PE), which are two different forms of the same disease [1] At present, venous thrombosis has become the third cause of cardiovascular disease and common complications of cancer, such as lung cancer [2]. VTE is a complex multi-factor disease, in which gene mutation plays an important role [3]. However, there are great ethnic and regional characteristics of gene mutation in VTE. Therefore, exploring the susceptible genes to provide the basis for the prevention and treatment of VTE will be one of the important research directions of comprehensive therapy for vascular diseases and cancer.

Methylenetetrahydrofolate reductase (MTHFR) is a homocysteine (Hey) metabolic regulatory enzyme. It could reduce N5, N10-methylene tetrahydro folic acid to N5- methyl tetrahydro folic acid, and the latter has the ability to maintain the stability of plasma Hey. The decrease of MTHFR activity will give rise to impaired Hey methylation and further hyperhomocysteinemia, which could destroy vascular endothelium and change platelet function as well as blood coagulation state, finally participating in the pathogenesis of VTE. Both the mutation of MTHFR gene at 677site from base cytosine (C) to thymine (T) and the mutation of MTHFR gene at 1298site from adenine (A) to cytosine (C) could cause amino acid mistranslation, further decrease MTHFR activity and increase Hey level.

In recent years, many studies about the relationship between MTHFR gene polymorphism and the risk of VTE have been reported, but with inconsistent conclusions. Some hold the view that MTHFR/C677T was a significant risk factor of VTE, which demonstrates the association of MTHFR C677T polymorphism with the susceptibility to VTE [4], but some not [5]. In addition to MTHFR C677T polymorphism, it is also a highly debated issue that whether MTHFR A1298C polymorphism could increase the susceptibility to VTE. Therefore, we conducted this meta-analysis to explore the correlation between MTHFR C677T polymorphism as well as MTHFR A1298C polymorphism and the risk of VTE, providing theoretical basis for the prevention and treatment of VTE.

Materials and methods

Search strategy and selection criteria

This systematic review and meta-analysis is reported in accordance with the Preferred Items for Systematic Reviews and Meta-analysis (PRISMA) Statement. Literature was retrieved by formal search of electronic databases (Pubmed, embase, Cochrane library, scopus, OvidSP, Wiley Online library, Springer link, EBSCO, Elsevier Science Direct, Google scholar) without date limitation. To achieve the maximum sensitivity of the search strategy, we used appropriated free text and thesaurus terms including “methylenetetrahydrofolate reductase or MTHFR”, “Venous thromboembolism or VTE”, “polymorphism or mutation or variant”. We also search reference lists of related articles by hand to obtain more studies. The retrieval strategy of Pubmed is as follows: (((((polymorphism[Title/Abstract] OR mutation[Title/Abstract] OR variant[Title/Abstract])) OR “Polymorphism, Genetic”[Mesh])) AND ((deep venous thrombosis[Title/Abstract]) OR “Venous thromboembolism”[Mesh])) AND (((Methylenetetrahydrofolate Reductase (NADPH) or Methylene-THF Reductase (NADPH) or Methylenetetrahydrofolate Reductase or 5,10-Methylenetetrahydrofolate Reductase (NADPH) or Methylene Tetrahydrofolate Reductase or Tetrahydrofolate Reductase, Methylene)) OR “Methylenetetrahydrofolate Reductase (NADPH2)”[Mesh]).

Inclusion criteria: (1) Patients with VTE, including venous thrombosis and deep venous thrombosis; (2) Methylenetetrahydrofolate reductase C677T polymorphism and A1298C polymorphism; (3) Sufficient genotype data; (4) P value for Hardy–Weinberg equilibrium test > 0.05; (5) Case–control design.

Data extraction and quality assessment

Two authors independently extracted the original data. As recommended by the Cochrane Non-Randomized Studies Methods, Newcastle–Ottaw scale (NOS) was used to assess the quality of included researches and a total score of included studies ranging from 7 to 9 was deemed high quality. Disagreement was resolved by discussion. The extracted data were consisted of the follow items: the first author’s name, publication year, country, race, genotype distribution data, total number of cases and controls.

Statistical analysis

Meta-analysis was performed to calculate pooled ORs (Odds ratios) with 95% CI (Confidence interval) by using Review manager 5.3. Heterogeneity among studies was assessed by I2 statistic. I2> 50% is indicative of heterogeneity [6], random effects model will be used. Otherwise, fixed effect will be implemented. Chi-square distribution was employed to measure the deviation of genotype distribution from Hardy–Weinberg equilibrium in control group. Subgroup analysis was conducted to explore the sources of heterogeneity and the differences between races. We also perform sensitive analysis by changing effect models. Finally, funnel plots were carried out to evaluate publication bias. The P-value <0.05 in all tests was considered significant.

Results

Flowchart and characteristic of including studies

There are 32 eligible studies meeting to our inclusion criteria [4,5,7–36], including 31 papers for MTHFR C677T polymorphism [4,5,7–25,27–36] and 6 papers for MTHFR A1298C polymorphism [12,15,19,21,26,30]. The details of flow diagram for literature selection were shown in Figure 1. Among included studies, a total of 15 for the Asian [5,8,9,11,13,14,17,18,21–24,27,34,36], mainly in China, and 17 for the Caucasian [4,7,10,12,15,16,19,20,25,26,28–33,35]. Due to the comprehensive search, the publication year is from 1999 to 2019. The total sample size is nearly 20,000, containing 8223 patients and 10,859 controls. The main features of eligible studies are summarized in Tables 1 and 2.

Flow diagram for literature selection

Figure 1
Flow diagram for literature selection
Figure 1
Flow diagram for literature selection
Table 1
Characteristics of include studies about MTHFR C677T polymorphism
Author, yearCountryRaceCase groupControl grouppHWENOS
CCCTTTTotalCCCTTTTotal
Jang, 2013 South Korea Asian 74 82 47 203 140 203 60 403 0.62 
Xu, 2019 China Asian 42 28 31 101 70 26 24 120 0.10 
Yin, 2012 China Asian 171 157 112 440 182 190 68 440 0.30 
Kailibinuer, 2012 China Asian 22 31 35 88 30 45 11 86 0.65 
Wang, 2004 China Asian 13 28 17 58 19 32 58 0.51 
Qiu, 2002 China Asian 23 32 14 69 42 47 12 101 0.98 
Hsu, 2001 China Asian 60 40 107 55 44 107 0.98 
Lu, 2002 China Asian 18 42 30 90 31 66 46 143 0.73 
Guo, 2002 China Asian 26 33 63 16 35 29 80 0.66 
Zheng, 2000 China Asian 12 31 10 53 62 45 15 122 0.34 
Lin, 2000 China Asian 53 50 112 76 41 125 0.75 
He, 2010 China Asian 15 27 21 63 26 36 13 75 1.00 
Li, 2015 China Asian 71 107 68 246 97 155 40 292 0.21 
Gao, 2008 China Asian 16 34 14 64 14 39 11 64 0.21 
Dong, 2013 China Asian 16 37 15 68 15 41 12 68 0.23 
Hsu TS, 2001 China Asian 48 28 83 43 33 82 1.00 
Karmadonova, 2014 Russia Caucasian 76 79 19 174 226 201 34 461 0.50 
Spiroski, 2008 Macedonia Caucasian 20 33 10 63 34 35 11 80 0.92 
Bezemer, 2007 Netherlands Caucasian 2044 1891 440 4375 2245 2094 517 4856 0.68 
Almawi, 2005 America Caucasian 80 77 41 198 350 270 77 697 0.08 
Miranda, 2002 Netherlands Caucasian 67 90 14 171 233 186 42 461 0.86 
Zalavras, 2002 Greece Caucasian 70 82 24 176 117 153 30 300 0.14 
Amparo, 2010 Spain Caucasian 14 19 42 23 42 14 79 0.79 
Tawfik, 2012 Egypt Caucasian 20 25 49 22 24 0.01 
Hanson, 2001 America Caucasian 58 63 16 137 130 158 41 329 0.80 
Ray, 2001 Canada Caucasian 49 61 19 129 72 44 13 129 0.30 
Gerald, 2000 Australia Caucasian 67 73 15 155 122 141 35 298 0.84 
Phillip, 2000 Canada Caucasian 25 28 12 65 21 35 64 0.53 
Ben, 2012 Tunisia Caucasian 20 26 101 79 17 197 0.96 
Kupeli, 2011 Turkey Caucasian 49 24 80 78 26 104 0.35 
Lupi-Herrera, 2018 Mexico Caucasian 77 106 29 212 33 54 35 122 0.45 
Author, yearCountryRaceCase groupControl grouppHWENOS
CCCTTTTotalCCCTTTTotal
Jang, 2013 South Korea Asian 74 82 47 203 140 203 60 403 0.62 
Xu, 2019 China Asian 42 28 31 101 70 26 24 120 0.10 
Yin, 2012 China Asian 171 157 112 440 182 190 68 440 0.30 
Kailibinuer, 2012 China Asian 22 31 35 88 30 45 11 86 0.65 
Wang, 2004 China Asian 13 28 17 58 19 32 58 0.51 
Qiu, 2002 China Asian 23 32 14 69 42 47 12 101 0.98 
Hsu, 2001 China Asian 60 40 107 55 44 107 0.98 
Lu, 2002 China Asian 18 42 30 90 31 66 46 143 0.73 
Guo, 2002 China Asian 26 33 63 16 35 29 80 0.66 
Zheng, 2000 China Asian 12 31 10 53 62 45 15 122 0.34 
Lin, 2000 China Asian 53 50 112 76 41 125 0.75 
He, 2010 China Asian 15 27 21 63 26 36 13 75 1.00 
Li, 2015 China Asian 71 107 68 246 97 155 40 292 0.21 
Gao, 2008 China Asian 16 34 14 64 14 39 11 64 0.21 
Dong, 2013 China Asian 16 37 15 68 15 41 12 68 0.23 
Hsu TS, 2001 China Asian 48 28 83 43 33 82 1.00 
Karmadonova, 2014 Russia Caucasian 76 79 19 174 226 201 34 461 0.50 
Spiroski, 2008 Macedonia Caucasian 20 33 10 63 34 35 11 80 0.92 
Bezemer, 2007 Netherlands Caucasian 2044 1891 440 4375 2245 2094 517 4856 0.68 
Almawi, 2005 America Caucasian 80 77 41 198 350 270 77 697 0.08 
Miranda, 2002 Netherlands Caucasian 67 90 14 171 233 186 42 461 0.86 
Zalavras, 2002 Greece Caucasian 70 82 24 176 117 153 30 300 0.14 
Amparo, 2010 Spain Caucasian 14 19 42 23 42 14 79 0.79 
Tawfik, 2012 Egypt Caucasian 20 25 49 22 24 0.01 
Hanson, 2001 America Caucasian 58 63 16 137 130 158 41 329 0.80 
Ray, 2001 Canada Caucasian 49 61 19 129 72 44 13 129 0.30 
Gerald, 2000 Australia Caucasian 67 73 15 155 122 141 35 298 0.84 
Phillip, 2000 Canada Caucasian 25 28 12 65 21 35 64 0.53 
Ben, 2012 Tunisia Caucasian 20 26 101 79 17 197 0.96 
Kupeli, 2011 Turkey Caucasian 49 24 80 78 26 104 0.35 
Lupi-Herrera, 2018 Mexico Caucasian 77 106 29 212 33 54 35 122 0.45 

pHWE, P values for Hardy–Weinberg equilibrium test.

Table 2
Characteristics of include studies about MTHFR A1298C polymorphism
Author, yearCountryRaceCase groupControl grouppHWENOS
AAACCCTotalAAACCCTotal
Hanson, 2001 America Caucasian 60 62 15 137 164 139 26 329 0.90 
Karmadonova, 2014 Russia Caucasian 67 96 11 174 204 196 49 449 0.98 
Martine, 1999 France Caucasian 65 86 17 168 195 215 46 456 0.49 
Li, 2015 China Asian 163 65 18 246 180 97 15 292 0.92 
Ray, 2001 Canada Caucasian 68 49 12 129 69 49 11 129 0.86 
Spiroski, 2008 Macedonia Caucasian 32 29 63 38 39 80 0.18 
Author, yearCountryRaceCase groupControl grouppHWENOS
AAACCCTotalAAACCCTotal
Hanson, 2001 America Caucasian 60 62 15 137 164 139 26 329 0.90 
Karmadonova, 2014 Russia Caucasian 67 96 11 174 204 196 49 449 0.98 
Martine, 1999 France Caucasian 65 86 17 168 195 215 46 456 0.49 
Li, 2015 China Asian 163 65 18 246 180 97 15 292 0.92 
Ray, 2001 Canada Caucasian 68 49 12 129 69 49 11 129 0.86 
Spiroski, 2008 Macedonia Caucasian 32 29 63 38 39 80 0.18 

pHWE, P values for Hardy–Weinberg equilibrium test.

Meta-analysis results

MTHFR C677T polymorphism and the susceptibility to Venous thromboembolism

The pooled results suggested that there were significant differences in all models of MTHFR C677T polymorphism, including CC+CT vs TT: OR = 0.68 (0.56, 0.83) (Figure 2), CC vs CT +TT: OR = 0.82 (0.72, 0.94) (Figure 3), CT vs TT: OR = 0.65 (0.52, 0.81) (Figure 4), CC vs TT: OR = 0.73 (0.60, 0.89) (Figure 5) and C vs T: OR = 0.80 (0.71, 0.90) (Figure 6). Due to significant heterogeneity, random effect models were used in all the comparisons. Subgroup analysis showed that, for the Asian, there was no heterogeneity in all the comparisons. But for the Caucasian, no significant association was observed, which tells us the source of heterogeneity and the difference between races (Table 3). Table 4 detailed the results of sensitive analysis, which demonstrated no significant change appeared in all pooled results after the transformation of random effect models into fixed effect models. The funnel plots showed good symmetry bias in all comparisons.

MTHFR C677T polymorphism and the susceptibility to Venous thromboembolism (CC+CT vs TT)

Figure 2
MTHFR C677T polymorphism and the susceptibility to Venous thromboembolism (CC+CT vs TT)
Figure 2
MTHFR C677T polymorphism and the susceptibility to Venous thromboembolism (CC+CT vs TT)

MTHFR C677T polymorphism and the susceptibility to Venous thromboembolism (CC vs CT+TT)

Figure 3
MTHFR C677T polymorphism and the susceptibility to Venous thromboembolism (CC vs CT+TT)
Figure 3
MTHFR C677T polymorphism and the susceptibility to Venous thromboembolism (CC vs CT+TT)

MTHFR C677T polymorphism and the susceptibility to Venous thromboembolism (CT vs TT)

Figure 4
MTHFR C677T polymorphism and the susceptibility to Venous thromboembolism (CT vs TT)
Figure 4
MTHFR C677T polymorphism and the susceptibility to Venous thromboembolism (CT vs TT)

MTHFR C677T polymorphism and the susceptibility to Venous thromboembolism (CC vs TT)

Figure 5
MTHFR C677T polymorphism and the susceptibility to Venous thromboembolism (CC vs TT)
Figure 5
MTHFR C677T polymorphism and the susceptibility to Venous thromboembolism (CC vs TT)

MTHFR C677T polymorphism and the susceptibility to Venous thromboembolism (C vs T)

Figure 6
MTHFR C677T polymorphism and the susceptibility to Venous thromboembolism (C vs T)
Figure 6
MTHFR C677T polymorphism and the susceptibility to Venous thromboembolism (C vs T)
Table 3
Subgroup analysis of the relationship between MTHFR C677T polymorphism and the susceptibility to VTE
ComparisonGroupOR (95%CI)I2, P
CC+CT vs TT Total 0.68 (0.56, 0.83) 69%, <0.0001 
 Asian 0.54 (0.46, 0.65) 10%, 0.34 
 Caucasian 0.85 (0.63, 1.14) 69%, <0.0001 
CC vs CT+TT Total 0.82 (0.74, 0.93) 62%, <0.0001 
 Asian 0.79 (0.66, 0.95) 38%, 0.06 
 Caucasian 0.88 (0.72, 1.07) 71%, <0.0001 
CC vs TT Total 0.65 (0.52, 0.81) 69%, <0.0001 
 Asian 0.52 (0.42, 0.65) 19%, 0.24 
 Caucasian 0.81 (0.58, 1.12) 72%, <0.0001 
CT vs TT Total 0.73 (0.60, 0.89) 61%, <0.0001 
 Asian 0.56 (0.46, 0.68) 13%,0.31 
 Caucasian 0.93 (0.73, 1.19) 50%, 0.01 
C vs T Total 0.80 (0.71, 0.90) 76%, <0.0001 
 Asian 0.74 (0.65, 0.83) 41%, 0.04 
 Caucasian 0.88 (0.74, 1.04) 81%, <0.0001 
ComparisonGroupOR (95%CI)I2, P
CC+CT vs TT Total 0.68 (0.56, 0.83) 69%, <0.0001 
 Asian 0.54 (0.46, 0.65) 10%, 0.34 
 Caucasian 0.85 (0.63, 1.14) 69%, <0.0001 
CC vs CT+TT Total 0.82 (0.74, 0.93) 62%, <0.0001 
 Asian 0.79 (0.66, 0.95) 38%, 0.06 
 Caucasian 0.88 (0.72, 1.07) 71%, <0.0001 
CC vs TT Total 0.65 (0.52, 0.81) 69%, <0.0001 
 Asian 0.52 (0.42, 0.65) 19%, 0.24 
 Caucasian 0.81 (0.58, 1.12) 72%, <0.0001 
CT vs TT Total 0.73 (0.60, 0.89) 61%, <0.0001 
 Asian 0.56 (0.46, 0.68) 13%,0.31 
 Caucasian 0.93 (0.73, 1.19) 50%, 0.01 
C vs T Total 0.80 (0.71, 0.90) 76%, <0.0001 
 Asian 0.74 (0.65, 0.83) 41%, 0.04 
 Caucasian 0.88 (0.74, 1.04) 81%, <0.0001 

OR, odds ratio.

Table 4
Sensitive analysis about MTHFR C677T and A1298C Polymorphism and VTE susceptibility
ComparisonEffect modelOR (95%CI)
MTHFR C677T   
CC+CT vs TT Random 0.68 (0.56, 0.83) 
 Fixed 0.80 (0.73, 0.87) 
CC vs CT+TT Random 0.82 (0.74, 0.93) 
 Fixed 0.92 (0.87, 0.98) 
CC vs TT Random 0.65 (0.52, 0.81) 
 Fixed 0.80 (0.73, 0.88) 
CT vs TT Random 0.73 (0.60, 0.89) 
 Fixed 0.83 (0.75, 0.91) 
C vs T Random 0.80 (0.71, 0.90) 
 Fixed 0.90 (0.87, 0.95) 
MTHFR A1298C   
AA+AC vs CC Random 0.97 (0.71, 1.32) 
 Fixed 0.99 (0.74, 1.33) 
AA vs AC+CC Random 0.91 (0.77, 1.08) 
 Fixed 0.91 (0.77, 1.08) 
AA vs CC Random 0.90 (0.66, 1.23) 
 Fixed 0.91 (0.67, 1.25) 
AC vs CC Random 1.01 (0.67, 1.52) 
 Fixed 1.05 (0.77, 1.43) 
A vs C Random 0.95 (0.83, 1.07) 
 Fixed 0.95 (0.83, 1.07) 
ComparisonEffect modelOR (95%CI)
MTHFR C677T   
CC+CT vs TT Random 0.68 (0.56, 0.83) 
 Fixed 0.80 (0.73, 0.87) 
CC vs CT+TT Random 0.82 (0.74, 0.93) 
 Fixed 0.92 (0.87, 0.98) 
CC vs TT Random 0.65 (0.52, 0.81) 
 Fixed 0.80 (0.73, 0.88) 
CT vs TT Random 0.73 (0.60, 0.89) 
 Fixed 0.83 (0.75, 0.91) 
C vs T Random 0.80 (0.71, 0.90) 
 Fixed 0.90 (0.87, 0.95) 
MTHFR A1298C   
AA+AC vs CC Random 0.97 (0.71, 1.32) 
 Fixed 0.99 (0.74, 1.33) 
AA vs AC+CC Random 0.91 (0.77, 1.08) 
 Fixed 0.91 (0.77, 1.08) 
AA vs CC Random 0.90 (0.66, 1.23) 
 Fixed 0.91 (0.67, 1.25) 
AC vs CC Random 1.01 (0.67, 1.52) 
 Fixed 1.05 (0.77, 1.43) 
A vs C Random 0.95 (0.83, 1.07) 
 Fixed 0.95 (0.83, 1.07) 

OR, odds ratio.

MTHFR A1298C polymorphism and the susceptibility to VTE

Similar to C677T polymorphism, the comparisons of five models were conducted. As shown in Figure 7, none of any comparison exhibited significant difference statistically, with AA+AC vs CC: OR = 0.97 (0.71, 1.32) (Figure 7A), AA vs AC +CC: OR = 0.91 (0.77, 1.08) (Figure 7B), AA vs CC: OR = 0.90 (0.66, 1.23) (Figure 7C), AC vs CC: OR = 1.01 (0.67, 1.52) (Figure 7D) and A vs C: OR = 0.95 (0.83,1.07) (Figure 7E). Because of none heterogeneity, fixed effects were adapted. Sensitive analysis also suggested our results were stable (Table 4). Publication test failed to be conducted due to small sample included.

MTHFR A1298C polymorphism and the susceptibility to Venous thromboembolism ((A) AA+AC vs CC, (B) AA vs AC +CC, (C) AA vs CC, (D) AC vs CC, (E) A vs C)

Figure 7
MTHFR A1298C polymorphism and the susceptibility to Venous thromboembolism ((A) AA+AC vs CC, (B) AA vs AC +CC, (C) AA vs CC, (D) AC vs CC, (E) A vs C)
Figure 7
MTHFR A1298C polymorphism and the susceptibility to Venous thromboembolism ((A) AA+AC vs CC, (B) AA vs AC +CC, (C) AA vs CC, (D) AC vs CC, (E) A vs C)

Discussion

Although some meta-analysis about the relationship between the risk of VTE and MTHFR mutation have been reported, but the objects are mainly limited to C677T and Chinese. We not only expanded the population, including the Asian and Caucasian, but also explored the association of A1298C polymorphism and VTE susceptibility. Our results showed that, in all the comparisons of the gene phenotypic model, MTHFR C677T mutation could increase the risk of VTE in the Asian, but not in the Caucasian. In addition, there may be no association between MTHFR A1298C mutation and VTE susceptibility. Sensitive analysis and publication test suggested that our results were stable and reliable.

The human MTHFR gene, located on lp36.3 and with a cDNA length of 2.2 kb, is composed of 11(12) exons and 10(11) introns. MTHFR plays a key role in folic acid metabolism. The gene sequence of MTHFR is high conserved. If the gene sequence of 677 base cytosine C is mutated to thymine T, the valine generated by the mutation will replace the conserved alanine, which will lead to a serious decrease in the binding ability of MTHFR to flavin adenine dinucleotide [37]. The increased risk of many diseases caused by MTHFR mutation has been reported, such as congenital heart diseases [38], coronary artery disease [39], systemic lupus erythematosus [40] and cancer [41]. MTHFR’s thermal stability and enzyme activity were reduced due to the mutant T allele, resulting in hyperhomocysteine, which is an independent risk factor for VTE [42].

Zhang et al. [43] reported T allele, CT genotype, and TT genotype were associated with the risk of VTE in the Chinese population. Similar to our results, a pooled study of three Asian populations also showed the TT homozygous genotype could increase and the susceptibility to VTE [17]. Den et al. [44] reported that, in non-north American populations, the mutant T allele increased the risk of VTE compared with the wild-type C allele, but not in north American populations. The reason may be that higher intake of folic acid and riboflavin in north American populations reduces the risk of high homocysteine in carriers of the mutant T allele. Our study demonstrated that, regardless of gene models, C677T mutation couldn’t increase VTE susceptibility in the Caucasian.

1298 site of MTHFR is located in the exon 7 and encodes regulatory region of s-adenosine methionine. Likewise, the mutation of adenine (A) to cytosine (C) in this site causes glutamate to be replaced by alanine, decreasing the phosphorylation of serine and cysteine and thus affecting the expression of MTHFR as well [45]. As another MTHFR gene mutation, the relationship between MTHFR A1298C polymorphism and the risk of disease is also explored, such as Alzheimer’s disease [46] and lung cancer [47]. Our study is the first meta-analysis to explore the relationship between MTHFR A1298C polymorphism and VTE susceptibility. Six studies were included, in which only one paper was from the Asian, so we didn’t conduct subgroup analysis and publication test. Finally, no significant association was observed in any comparison of all gene models.

Because of the comprehensive search, large samples were included. Subgroup analysis suggested race is the source of heterogeneity and there exists great difference between the Asian and Caucasian. Of course, there were some limitation we need point out. Owe to insufficient data provided, confounding factors, including age, gender, body mass index, smoking status, drink abuse and other environmental factors, are difficult to fully be adjusted. Then, the controls were not uniformly defined, such as population- and hospital-based controls, and the latter may not necessarily be representative of the underlying source population.

In conclusions, our study uncovered that MTHFR C677T polymorphism may increase susceptibility to VTE in the Asian, but not in the Caucasian. There may be no association between MTHFR A1298C polymorphism and VTE. Our conclusion requires further focus on the effect of gene–gene and gene–environment interaction as well as different VTE types.

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Funding

This work was supported by Key R&D projects in social development in shaanxi province [grant number 2017SF-003]; new technology new business of Xijing hospital [grant number XJGX15H01].

Author Contribution

M.G. and N.F. conceived and designed the methods, extracted the original data, and drafted the manuscript. M.G., M.X.Z. and N.F. performed statistical analysis and interpreted results. X.Y.T. and X.P.Z. revised the manuscript and had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of data analysis.

Abbreviations

     
  • CI

    confidence interval

  •  
  • MTHFR

    methylenetetrahydrofolate reductase

  •  
  • NOS

    Newcastle–Ottawa Scale

  •  
  • OR

    odds ratio

  •  
  • pHWE

    P values for Hardy–Weinberg equilibrium test

  •  
  • PRISMA

    Preferred Items for Systematic Reviews and Meta-analysis

  •  
  • VTE

    venous thromboembolism

References

References
1.
Schulman
S.
,
Ageno
W.
and
Konstantinides
S.V.
(
2017
)
Venous thromboembolism: Past, present and future
.
Thromb. Haemost.
117
,
1219
1229
[PubMed]
2.
Kuderer
N.M.
,
Poniewierski
M.S.
,
Culakova
E.
,
Lyman
G.H.
,
Khorana
A.A.
,
Pabinger
I.
et al.
(
2018
)
Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK)
.
Oncologist
23
,
247
255
[PubMed]
3.
Hotoleanu
C.
(
2017
)
Genetic Risk Factors in Venous Thromboembolism
.
Adv. Exp. Med. Biol.
906
,
253
272
[PubMed]
4.
Abudureheman
K.
,
Mahemuti
A.
,
Xia
Y.N.
and
Hu
X.M.
(
2012
)
Association between gene polymorphisms of methylenetetrahydrofolate reductase and plasma homocysteine in Uygur patients with venous thromboembolism
.
Zhonghua Xin Xue Guan Bing Za Zhi
40
,
1030
1036
[PubMed]
5.
He
J.A.
,
Hu
X.H.
,
Fan
Y.Y.
,
Yang
J.
,
Zhang
Z.S.
,
Liu
C.W.
et al.
(
2010
)
Hyperhomocysteinaemia, low folate concentrations and methylene tetrahydrofolate reductase C677T mutation in acute mesenteric venous thrombosis
.
Eur. J. Vasc. Endovasc. Surg.
39
,
508
513
[PubMed]
6.
Ioannidis
J.P.
,
Patsopoulos
N.A.
and
Evangelou
E.
(
2007
)
Heterogeneity in meta-analyses of genome-wide association investigations
.
PLoS ONE
2
,
e841
[PubMed]
7.
Ben Salem-Berrabah
O.
,
Fekih-Mrissa
N.
,
N'Siri
B.
,
Ben Hamida
A.
,
Benammar-Elgaaied
A.
,
Gritli
N.
et al.
(
2012
)
Thrombophilic polymorphisms - factor V Leiden G1691A, prothrombin G20210A and MTHFR C677T - in Tunisian patients with cerebral venous thrombosis
.
J. Clin. Neurosci.
19
,
1326
1327
[PubMed]
8.
Dong
N.
,
Wang
B.
,
Chu
L.
and
Xiao
L.
(
2013
)
Plasma homocysteine concentrations in the acute phase after central retinal vein occlusion in a Chinese population
.
Curr. Eye Res.
38
,
1153
1158
[PubMed]
9.
Gao
W.
,
Wang
Y.S.
,
Zhang
P.
and
Wang
H.Y.
(
2008
)
MTHFR C677T mutation in central retinal vein occlusion: a case-control study in Chinese population
.
Thromb. Res.
121
,
699
703
[PubMed]
10.
Seinost
G.
,
Renner
W.
,
Brodmann
M.
and
Winkler
M.
(
2000
)
C677T Mutation in the Methylene Tetrahydrofolate Reductase Gene as a Risk Factor for Venous Thrombotic Disease in Austrian Patients
.
Thromb. Res.
100
,
405
407
[PubMed]
11.
Guo
C.
,
Guo
Q.
,
Gong
Y.
and
Bingxi
C.
(
2002
)
The C677T mutation In the methylenetetrahydrofolate reductase gene and Its association with deep vein thrombophilia In Shandong Hans
.
Chin. J. Med. Genet.
19
,
295
297
12.
Hanson
N.Q.
,
Aras
O.
,
Yang
F.
and
Tsai
M.Y.
(
2001
)
C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease
.
Clin. Chem.
47
,
661
666
[PubMed]
13.
Hsu
L.-A.
,
Ko
Y.-L.
,
Wang
S.-M.
and
Chang
C.-J.
(
2001
)
The C677T Mutation of the Methylenetetrahydrofolate Reductase Gene Is Not Associated with the Risk of Coronary Artery Disease or Venous Thrombosis among Chinese in Taiwan
.
Hum. Hered.
51
,
41
45
[PubMed]
14.
Hsu
T.S.
,
Hsu
L.A.
,
Chang
C.J.
,
Sun
C.F.
and
Ko
Y.L.
(
2001
)
Importance of hyperhomocysteinemia as a risk factor for venous thromboembolism in a Taiwanese population. A case-control study
.
Thromb. Res.
102
,
387
395
15.
Spiroski
I.
,
Kedev
S.
,
Antov
S.
,
Arsov
T.
,
Krstevska
M.
,
Dzhekova-Stojkova
S.
et al.
(
2008
)
Methylenetetrahydrofolate reductase (MTHFR-677 and MTHFR-1298) genotypes and haplotypes and plasma homocysteine levels in patients with occlusive artery disease and deep venous thrombosis
.
Acta Biochim. Pol.
55
,
587
594
[PubMed]
16.
Bezemer
I.D.
,
Doggen
C.J.M.
,
Vos
H.L.
and
Rosendaal
F.R.
(
2007
)
No Association Between the Common MTHFR 677C→T Polymorphism and Venous Thrombosis
.
Arch. Intern. Med.
167
,
497
501
[PubMed]
17.
Jang
M.J.
,
Jeon
Y.J.
,
Choi
W.I.
,
Choi
Y.S.
,
Kim
S.Y.
,
Chong
S.Y.
et al.
(
2013
)
The 677C>T mutation of the MTHFR gene increases the risk of venous thromboembolism in Koreans and a meta-analysis from Asian population
.
Clin. Appl. Thromb. Hemost.
19
,
309
314
[PubMed]
18.
Xu
J.
,
Li
K.
and
Zhou
W.
(
2019
)
Relationship between genetic polymorphism of MTHFR C677T and lower extremities deep venous thrombosis
.
Hematology
24
,
108
111
[PubMed]
19.
Karmadonova
N.A.
,
Shilova
A.N.
,
Kozyreva
V.S.
,
Subbotovskaya
A.I.
,
Klevanets
J.E.
and
Karpenko
A.A.
(
2015
)
Association of folate metabolism gene polymorphisms and pulmonary embolism: A case-control study of West-Siberian population
.
Thromb. Res.
135
,
788
795
[PubMed]
20.
Kupeli
E.
,
Verdi
H.
,
Simsek
A.
,
Atac
F.B.
and
Eyuboglu
F.O.
(
2011
)
Genetic mutations in Turkish population with pulmonary embolism and deep venous thrombosis
.
Clin. Appl. Thromb. Hemost.
17
,
E87
E94
[PubMed]
21.
Li
Z.
,
Yadav
U.
,
Mahemuti
A.
,
Tang
B.-P.
and
Upur
H.
(
2015
)
Association of MTHFR genetic polymorphisms with venous thromboembolism in Uyghur population in Xinjiang, China
.
Int. J. Clin. Exp. Med.
8
,
17703
17711
[PubMed]
22.
Lin
J.S.
,
Shen
M.C.
,
Tsai
W.
and
Bodo
L.
(
2000
)
The prevalence of C677T mutation in the methylenetetrahydrofolate reductase gene and its association with venous thrombophilia in Taiwanese Chinese
.
Thromb. Res.
97
,
89
94
[PubMed]
23.
Ling
Q.
,
Shengkai
Y.
and
Yaohong
S.
(
2002
)
Methylenetetrahydrofolate reductase gene polymorphism and deep-vein thrombosis
.
Chin. J. Lab. Med.
25
,
200
204
24.
Lu
Y.
,
Zhao
Y.
,
Liu
G.
,
Wang
X.
,
Liu
Z.
,
Chen
B.
et al.
(
2002
)
Factor V gene G1691A mutation, prothrombin gene G20210A mutation, and MTHFR gene C677T mutation are not risk factors for pulmonary thromboembolism in Chinese population
.
Thromb. Res.
106
,
7
12
[PubMed]
25.
Lupi-Herrera
E.
,
Soto-Lopez
M.E.
,
Lugo-Dimas
A.J.
,
Nunez-Martinez
M.E.
,
Gamboa
R.
,
Huesca-Gomez
C.
et al.
(
2019
)
Polymorphisms C677T and A1298C of MTHFR Gene: Homocysteine Levels and Prothrombotic Biomarkers in Coronary and Pulmonary Thromboembolic Disease
.
Clin. Appl. Thromb. Hemost.
25
,
1076029618780344
[PubMed]
26.
Martine
A.G.
,
Arnaud
E.
,
Nicaud
V.
,
Aubry
M.L.
,
Fiessinger
J.N.
,
Aiach
M.
et al.
(
1999
)
Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes
.
Thromb. Haemost.
81
,
506
510
[PubMed]
27.
Meitang
W.
,
Qiang
L.
and
Lai
H.F.
(
2004
)
Relationship of plasma homocysteine and folio acid levels and 510-methylenetetrahydrofolate reductase gene mutation th venous thromboembollsm
.
Chin. J. Intern. Med.
43
,
591
595
28.
Keijzer
M.B.A.J.
,
den Heijer
M.
,
Blom
H.J.
,
Bos
G.M.J.
,
Willems
H.P.J.
,
Gerrits
W.B.J.
et al.
(
2002
)
Interaction Between Hyperhomocysteinemia, Mutated Methylenetetrahydrofolatereductase (MTHFR) and Inherited Thrombophilic Factors in Recurrent Venous Thrombosis
.
Thromb. Haemost.
88
,
723
728
[PubMed]
29.
Isotalo
P.A.
,
Donnelly
J.G.
and
FCACB
(
2000
)
Prevalence of Methylenetetrahydrofolate Reductase Mutations in Patients With Venous Thrombosis
.
Mol. Diagn.
4
,
59
66
30.
Ray
J.G.
,
Langman
L.J.
,
Vermeulen
M.J.
,
Evrovski
J.
,
Yeo
E.L.
and
Cole
D.E.
(
2001
)
Genetics University of Toronto Thrombophilia Study in Women (GUTTSI): genetic and other risk factors for venous thromboembolism in women
.
Curr. Control. Trials Cardiovasc. Med.
2
,
141
149
[PubMed]
31.
Tawfik
N.M.
,
Deeb
M.E.
and
Nasr
A.S.
(
2012
)
Role of soluble P-selectin and methylenetetrahydrofolate reductase gene polymorphisms (677C>T) in Egyptian patients with venous thromboembolism
.
Blood Coagul. Fibrinolysis
23
,
537
542
[PubMed]
32.
Vaya
A.
,
Plume
G.
,
Bonet
E.
,
Carrasco
P.
and
Morales-Suarez-Varela
M.M.
(
2011
)
Hyperhomocysteinemia and the methylene tetrahydrofolate reductase C677T mutation in splanchnic vein thrombosis
.
Eur. J. Haematol.
86
,
167
172
[PubMed]
33.
Almawi
W.Y.
,
Tamim
H.
,
Kreidy
R.
,
Timson
G.
,
Rahal
E.
,
Nabulsi
M.
et al.
(
2005
)
A Case Control Study on the Contribution of Factor V-Leiden, Prothrombin G20210A, and MTHFR C677T Mutations to the Genetic Susceptibility of Deep Venous Thrombosis
.
J. Thromb. Thrombolysis
19
,
189
196
[PubMed]
34.
Yin
G.
,
Yan
L.
,
Zhang
Z.
,
Chen
K.
and
Jin
X.
(
2012
)
C677T methylenetetrahydrofolate reductase gene polymorphism as a risk factor involved in venous thromboembolism: a population-based case-control study
.
Mol. Med. Rep.
6
,
1271
1275
[PubMed]
35.
Zalavras
C.H.G.
,
Giotopoulou
S.
,
Dokou
E.
,
Mitsis
M.
and
Ioannou
H.V.
(
2002
)
Lack of association between the C677T mutation in the 5,10-methylenetetrahydrofolate reductase gene and venous thromboembolism in Northwestern Greece
.
Int. Angiol.
21
,
268
271
[PubMed]
36.
Zheng
Y.Z.
,
Tong
J.
,
Do
X.P.
,
Pu
X.Q.
and
Zhou
B.T.
(
2000
)
Prevalence of methylenetetrahydrofolate reductase C677T and its association with arterial and venous thrombosis in the Chinese population
.
Br. J. Haematol.
109
,
870
874
[PubMed]
37.
Liew
S.C.
and
Gupta
E.D.
(
2015
)
Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases
.
Eur. J. Med. Genet
58
,
1
10
[PubMed]
38.
Xu
A.
,
Wang
W.
and
Jiang
X.
(
2018
)
The roles of MTRR and MTHFR gene polymorphisms in congenital heart diseases: a meta-analysis
.
Biosci. Rep.
38
,
39.
Luo
Z.
,
Lu
Z.
,
Muhammad
I.
,
Chen
Y.
,
Chen
Q.
,
Zhang
J.
et al.
(
2018
)
Associations of the MTHFR rs1801133 polymorphism with coronary artery disease and lipid levels: a systematic review and updated meta-analysis
.
Lipids Health Dis.
17
,
191
[PubMed]
40.
Huang
Y.C.
,
Lai
I.W.
and
Chang
H.C.
(
2019
)
The Association of MTHFR C677T and MTR A2756G Gene Polymorphisms With the Risk of Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis
.
J. Clin. Rheumatol.
,
1
3
41.
Nie
F.
,
Yu
M.
,
Zhang
K.
and
Yang
L.
(
2020
)
Association of MTHFR gene polymorphisms with pancreatic cancer: meta-analysis of 17 case-control studies
.
Int. J. Clin. Oncol.
25
,
312
321
[PubMed]
42.
Liew
S.C.
and
Gupta
E.D.
(
2015
)
Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases
.
Eur. J. Med. Genet.
58
,
1
10
[PubMed]
43.
Zhang
P.
,
Gao
X.
,
Zhang
Y.
,
Hu
Y.
and
Ma
H.
(
2015
)
Association between MTHFR C677T polymorphism and venous thromboembolism risk in the Chinese population: a meta-analysis of 24 case-controlled studies
.
Angiology
66
,
422
432
[PubMed]
44.
Den Heijer
M.
,
Lewington
S.
and
Clarke
R.
(
2005
)
Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies
.
J Thromb. Haemost.
3
,
292
299
[PubMed]
45.
Shahzad
K.
,
Hai
A.
,
Ahmed
A.
,
Kizilbash
N.
and
Jamal
A.
(
2013
)
A Structured-based Model for the Decreased Activity of Ala222Val and Glu429Ala Methylenetetrahydrofolate Reductase (MTHFR) Mutants
.
Bioinformation
9
,
929
936
[PubMed]
46.
Liu
S.
,
Wu
Y.
,
Liu
X.
,
Zhou
J.
,
Wang
Z.
,
He
Z.
et al.
(
2017
)
Lack of association between MTHFR A1298C variant and Alzheimer's disease: evidence from a systematic review and cumulative meta-analysis
.
Neurol. Res.
39
,
426
434
[PubMed]
47.
Zhang
X.D.
,
Li
Y.T.
,
Yang
S.Y.
and
Li
W.
(
2013
)
Meta-analysis on MTHFR polymorphism and lung cancer susceptibility in East Asian populations
.
Biomed. Rep.
1
,
440
446
[PubMed]

Author notes

*

These authors have contributed equally to this work.

This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).